<DOC>
	<DOC>NCT00229138</DOC>
	<brief_summary>This study will investigate the safety, tolerability and efficacy of EC-MPS with tacrolimus at both reference and reduced levels. This study will take into account safety aspects such as decreased renal toxicity by reducing the overall exposure to tacrolimus.</brief_summary>
	<brief_title>Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male or female kidney transplantation patients, 18 to 70 years of age, receiving a primary cadaveric, living unrelated, or nonHLA identical living related donor kidney. The renal cold ischemic time (CIT) must be &lt;30 hours The age of the donor must be between 10 and 65 years Exclusion Criteria Patients who have previously received an organ transplant Patients who are recipients of a multiple organ transplants Recipients of non heartbeating donor organs ABO incompatibility against the donor Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>De novo kidney recipients,</keyword>
	<keyword>EC-MPS,</keyword>
	<keyword>tacrolimus,</keyword>
	<keyword>efficacy,</keyword>
	<keyword>safety,</keyword>
	<keyword>glomerular filtration rate</keyword>
	<keyword>Treatment in de novo kidney recipients</keyword>
</DOC>